SCA1 -overview of the disease and genetics
Spinocerebellar ataxia type 1 (SCA1) joined the ranks of the unstable nucleotide repeat disorders and specifically the CAG/ polyglutamine (polyQ) diseases in 1993 (Orr et al., 1993) . SCA1 patients have loss of coordination of the limbs and trunk, unstable gait, dysarthric speech, and nystagmus but may have other symptoms, including extrapyramidal dysfunction, dysautonomia, cognitive impairment, and motor and sensory impairments. SCA1 is characterized pathologically by loss of Purkinje cells in the cerebellar cortex and neuronal loss in brain stem nuclei and cerebellar dentate nuclei (Koeppen, 2005) . Individuals carrying a mutant SCA1 allele can have symptoms starting as early as the first decade. By the sixth decade disease penetrance is essentially complete.
SCA1 genetics dates back to the mid-late 1970s when use of HLA serological typing as genetic markers revealed an autosomal dominant form of ataxia linked to the HLA complex on chromosome 6 (Yakura et al., 1974; Jackson et al., 1977) . With the application of molecular genetic approaches, location of the SCA1 gene was refined on the short arm of chromosome 6 to a region about 15 CM distal to HLA-A (Rich et al., 1987; Keats et al., 1991) . With its cloning, the SCA1 gene was found to span 450 kb of DNA at 6p22.3 and consists of nine exons (Banfi et al., 1994) . The SCA1 transcript is 10,660 bases in length with the first seven exons encoding the 5 0 untranslated region and exons eight and nine containing the Ataxin-1 (ATXN1) coding region (816 amino acids in Spinocerebellar ataxia type 1 (SCA1) is one an intriguing set of nine neurodegenerative diseases caused by the expansion of a unstable trinucleotide CAG repeat where the repeat is located within the coding of the affected gene, i.e. the polyglutamine (polyQ) diseases. A gain-of-function mechanism for toxicity in SCA1, like the other polyQ diseases, is thought to have a major role in pathogenesis. Yet, the specific nature of this gain-of-function is a matter of considerable discussion. An issue concerns whether toxicity stems from the native or normal function of the affected protein versus a novel function induced by polyQ expansion. For SCA1 considerable evidence is accumulating that pathology is mediated by a polyQ-induced exaggeration of a native function of the host protein Ataxin-1 (ATXN1) and that phosphorylation of S776 regulates its interaction with other cellular protein and thereby function. In addition, this posttranslational modification modulates toxicity of ATXN1 with an expanded polyglutamine.
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